The Prophylaxis against Early Ventilator Associated Lower Respiratory Tract Infection (PREVENT LRTI) trial. A phase 2 multi-centre, randomized, double-blind, placebo-controlled parallel group clinical trial.

Medical Research Institute of New Zealand0 个研究点目标入组 5 人开始时间: 2023年9月4日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1.Aged greater than or equal to 18 years AND
•2.Invasively mechanically ventilated with one or more of the following acute brain injuries/conditions:
•(i)Ischaemic stroke
•(ii)Intracerebral haemorrhage
•(iii)Status epilepticus
•(iv)Subarachnoid haemorrhage
•(v)Suspected hypoxic ischaemic encephalopathy following resuscitation from cardiac arrest
•(vi)Traumatic brain injury.
•3.Expected to be invasively ventilated (via endotracheal tube or tracheostomy) in the ICU until at least the day after tomorrow.

•1.Being treated with antibiotics to treat a known or suspected infection
•2.Has been treated with antibiotics for a known or suspected infection in the previous 7 days
•3.On prophylactic antibiotics except for peri-operative prophylaxis with cephazolin (or the treating clinician intends administering prophylactic antibiotics apart from peri-operative prophylaxis with cephazolin.) (SDD is counted as prophylactic antibiotics for the purposes of this exclusion)
•4.More than 12 hours since intubation (or tracheostomy insertion)
•5.More than 72 hours since hospital admission
•6.Documented allergy or other contraindication to ceftriaxone
•7.Death is deemed to be inevitable as a result of the current acute illness and either the treating clinician, the patient or the substitute decision maker are not committed to full active treatment.

发起方